Elpiscience Appoints Dr. Steve Chin as Chief Medical Officer

Janurary 06 , 2020 15:00

Shanghai, January 6, 2020. Elpiscience Biopharma, Ltd., a clinical-stage biopharmaceutical company announces the appointment of Steve Chin, M.D. as Chief Medical Officer.

Dr. Chin brings to the company many years of experience in medical oncology and clinical development in the pharmaceutical industry.

Prior to joining Elpiscience, Dr. Chin was a Senior Medical Director of immuno-oncology, Global Clinical Development at AstraZeneca. There, Dr. Chin provided leadership and expertise to enable new investment decisions in oncology therapeutic development, which involved the successful development of clinical strategy, determining the direction of regulatory interaction and coordination/execution of new clinical trials. Prior to his career at AstraZeneca, Dr. Chin was a Global GI Oncology Lead at Eli Lilly. He was involved in the transfer of cetuximab (Erbitux) full rights in North America from BMS to Lilly, led regulatory submission for Erbitux label updates, and fulfilled Erbitux post-marketing commitment.


Dr. Chin started his career as a medical oncologist and served as an assistant professor in the Division of Hematology/Oncology at the Medical University of South Carolina in Charleston. He was a clinical investigator with a special interest in cancer therapeutic development and correlative studies. Over his career, Dr. Chin has served as PI or Co-I in >20 active clinical trials.


Dr. Darren Ji, CEO and Co-Founder of Elpiscience stated, “We are elated to have Steve join us as Chief Medical Officer on our journey to find truly effective therapies in cancer immunotherapy. Steve brings abundant experience in both medical practices and drug development in the oncology space. His joining is extremely timely as we are rapidly advancing our clinical programs both in China and across the world. Steve’s extensive global clinical development experience in cancer immunotherapy will significantly strengthen our clinical development capability and accelerate the development of next-generation immunotherapy for patients.”

Dr. Steve Chin commented, “I’m thrilled about the rapid progress that Elpiscience has made in establishing a broad portfolio and an expanding pipeline of immuno-oncology molecules. It is my great honor to be a part of Elpiscience. I look forward to working with this exceptional team to drive the development of next-generation immuno-oncology therapeutics for the benefit of cancer patients in China and worldwide.”

About Elpiscience 

Elpiscience is a clinical-stage biopharmaceutical company focusing on cancer immunotherapy. The company is committed to leading the next generation of cancer immunotherapies for the benefit of cancer patients worldwide. Elpiscience has a pipeline of more than 10 innovative molecules with its most advanced asset, ES101, already in clinical trials. Elpiscience’s innovations cover a wide range of immunology targets with a focus on innate immunity and tumor microenvironment.